Actively Recruiting

Phase Not Applicable
Age: 22Years +
FEMALE
ID06885931

Exploratory Safety and Feasibility Study of Personalized Adaptive Pudendal Neuromodulation for Mixed Urinary Incontinence and Extended Indications Using an Implanted Picostim II System

Led by Amber Therapeutics Ltd · Updated on 2026-05-15

86

Participants Needed

7

Research Sites

135 weeks

Total Duration

On this page

AI-Summary

What this Trial Is About

Researchers are evaluating the safety and feasibility of a personalized adaptive pudendal neuromodulation system called Picostim II for women experiencing mixed urinary incontinence and related conditions. This exploratory study focuses on women aged 22 years and older who have not responded to or tolerated conservative treatments for urinary incontinence symptoms lasting at least six months. The study includes participants with mixed urinary incontinence and those with extended indications such as stress urinary incontinence, urge urinary incontinence, and chronic pelvic pain. All participants will receive the Amber UI system, an implanted device designed to provide pudendal neuromodulation. The study involves two groups: one with mixed urinary incontinence and another with extended indications. The device is implanted and personalized to each participant's needs, with follow-up and monitoring scheduled over 12 months. Researchers will observe procedural and device-related safety, device deficiencies, and the need for any surgical reintervention during this period. Participants will undergo various assessments including changes in urinary distress, frequency of urinary events, pad test weight, quality of life, anxiety, and health questionnaires over the course of 12 months. The primary safety outcomes focus on adverse events related to the procedure and device. Follow-up visits will help track the device's use, participant adherence, and overall health status. The total study duration for each participant includes baseline evaluation and monitoring over a year after implantation.

CONDITIONS

Brief Title

Augmenting Urinary Reflex Activity Study 4 (Including eXtended Indications)

Who Can Participate

Age: 22Years +
FEMALE

Eligibility Criteria

Eligible

You may qualify if you...

  • Female (sex at birth)
  • Aged 22 years or older at the time of consent
  • Self-reports both stress and urge urinary incontinence episodes
  • Failed or could not tolerate conservative treatments as determined by healthcare provider
  • Urinary incontinence symptoms lasting at least 6 months before screening
  • Able and willing to sign informed consent
  • Able to participate in all testing and follow-up visits
  • Mobile and able to use a toilet
  • Capable of independently using the device components after training (per Investigator's opinion)
Not Eligible

You will not qualify if you...

  • Pregnant, breastfeeding, or planning pregnancy
  • Unwilling or unable to use contraception during sexual activity for study duration
  • Unprepared to inactivate device if pregnancy occurs during or after study
  • Significant medical conditions interfering with study or device use (per Investigator's opinion)
  • History of major psychiatric or personality disorder
  • Neurological conditions affecting bladder function (e.g., stroke, MS, Parkinson's, neuropathy, spinal cord injury)
  • Uncontrolled diabetes (HbA1C 65 7.0)
  • Cancer history within 5 years except low-risk types
  • Taking anticoagulant or antiplatelet drugs that cannot be paused before surgery
  • Safety concerns as judged by Investigator
  • Currently in another interventional study (except observational)
  • Participation in vigorous physical activities that cannot be stopped for 6 weeks post-implant
  • Unwilling to stop scuba diving below 10 meters
  • BMI 65 40 kg/m2 or waist circumference > 127 cm
  • Allergic reactions to titanium, zirconia, polyurethane, epoxy, or silicone
  • Skin, orthopedic, or neurological issues at implant site
  • Planned exposure to MRI, diathermy, medical microwave, ultrasound, or RF energy
  • Existing implanted neurostimulator, pacemaker, or defibrillator
  • Diagnosed interstitial cystitis or bladder pain syndrome
  • Bladder emptying disorders or neurogenic bladder
  • High post-void residual urine (>100 ml)
  • Pelvic organ prolapse at or below hymenal level
  • Urinary tract obstruction
  • Current or frequent urinary tract infections
  • Vesicoureteral reflux or bladder stones
  • History of bladder tumor
  • Pudendal nerve entrapment or severe nerve damage
  • Previous pudendal nerve stimulation with implanted lead
  • Previous sacral neuromodulation failure
  • Major urethral or bladder surgery
  • Recent stress urinary incontinence or prolapse surgeries
  • Recent bladder botox injections

AI-Screening

AI-Powered Screening

Complete this quick 3-step screening to check your eligibility

1
2
3
+1

Your Study Journey

Screening

Duration - 2 to 4 weeks

Participants are screened for eligibility to participate in the trial.

1 visit (in-person)

Implementation

Duration - Up to 12 months

Participants receive the implanted Picostim II system for pudendal neuromodulation to treat urinary incontinence and extended indications.

Multiple visits for device programming and monitoring during the study period

Follow-up

Duration - Up to 12 months

Participants are monitored for safety, device-related events, and treatment effectiveness after device implantation.

Regular follow-up visits over 12 months

Trial Site Locations

Total: 7 locations

1

UZ Leuven

Leuven, Herestraat 49, Belgium, 3000

Actively Recruiting

2

Universitair Ziekenhuis Antwerpen

Edegem, Belgium, 655, 2650

Actively Recruiting

3

Ghent University Hospital

Ghent, Belgium, 9000

Actively Recruiting

4

Maastricht UMC

Maastricht, Netherlands, 6229 HX

Actively Recruiting

5

Southmead Hospital

Bristol, United Kingdom

Actively Recruiting

6

University College London Hospital

London, United Kingdom, NW1 2BU

Actively Recruiting

7

Guy's Hospital

London, United Kingdom

Not Yet Recruiting

Loading map...

Research Team

A

Amber Clinical Affairs

How is the study designed?

Study Type

INTERVENTIONAL

Masking

NONE

Allocation

NON_RANDOMIZED

Model

PARALLEL

Primary Purpose

TREATMENT

Number of Arms

2

Similar Trials

A Multicenter, Randomized, Double-blind, Dose-parallel, Plac...

Chronic Pelvic Pain

Actively Recruiting

1 location

Study to Assess the Safety and Effectiveness of the UrOActiv...

Stress Urinary Incontinence (SUI)

Actively Recruiting

21 locations

Frequently Asked Questions

Have more questions? Get in touch with our team for quick support

Not the Right Trial for You?

Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.

Already have an account? Log in here